Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScience Sprt Regulatory News (SIS)

Share Price Information for Science Sprt (SIS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.00
Bid: 18.50
Ask: 19.50
Change: 0.00 (0.00%)
Spread: 1.00 (5.405%)
Open: 19.00
High: 19.00
Low: 19.00
Prev. Close: 19.00
SIS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Year Trading Update

14 Jul 2021 07:00

RNS Number : 1381F
Science in Sport PLC
14 July 2021
 

14 July 2021

AIM: SIS

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

 

 

Science in Sport plc

("Science in Sport" or "the Company")

 

Half Year Trading Update

 

Returning to 20%+ Revenue Growth

 

Science in Sport, the premium performance nutrition company serving elite athletes, sports enthusiasts and the active lifestyle community, is pleased to announce a trading update for the first six months of its current financial year ending 31 December 2021.

 

Results Overview

After an encouraging start in January and February, sales continued to recover well, gaining momentum through the second quarter, with record monthly sales in June. This period of profitable growth, together with positive prospects for the second half, including new product launches, places the Company in a strong position to meet market expectations for the full year.

 

Revenue for the first six months increased by 24% to c. £29.3m, over the same period last year (H1 2020: £23.6m). Both brands, PhD Nutrition, an active lifestyle nutrition brand, and SIS, a leading endurance nutrition brand among elite athletes and professional sports teams, contributed strong double-digit growth, generating sales of £13.4m and £15.9m respectively (H1 2020: PhD, £11.7m, and SIS, £11.9m). New product launches accounted for 26% of revenue growth in H1.

 

Underlying EBITDA1 profit increased to £0.6m, continuing the strong upward trend (H1 2020: loss of £0.2m), and after an estimated one-off £0.6m negative impact from Brexit. Gross margin increased to 52% (H1 2020: 48%), driven by supply chain efficiencies and continued sales shift to online.

 

The Company's capital investment programme was accelerated, with £2.7m expended in the first half, compared to £0.9m in the same period last year. This investment supported the launch of a new customer data platform, which will drive ongoing online sales growth, and the first phase of investment at the new supply chain facility in Blackburn, which is currently scheduled to open in late Q1 2022. Significant further investment is planned in H2.

 

Reflecting the accelerated investment, the Group's cash position at 30 June 2021 was £8.2m (31 December 2020: £10.5m), slightly better than expected. The Company has an £8.0m debt facility, which remains unused.

 

1 before interest, tax, depreciation, amortisation, share based payments and foreign exchange variance on intercompany balances

 

 

Online sales

Online sales rose strongly, up by 44% to £15.7m (H1 2020: £10.9m). Online sales via the Group's own digital platforms were up by 35% and via third-party marketplace sites up by 53%.

 

In the important market of the US, sales increased by 60% to £2.4m (H1 2020: £1.5m), and PhD and SiS websites were launched in Japan and South Korea, supporting international expansion plans. Further site launches in the Middle East and India are scheduled for the second half.

 

Online sales accounted for 54% of total sales in the first half (H1 2020: 46%), and remain a key focus of investment as part of the strategic growth plan.

 

Retail sales

Despite being adversely impacted by pandemic restrictions, UK retail sales rose by 8% to £8.4m (H1 2020: £7.7m). International retail sales at £5.2m were 6% ahead (H1 2020: £4.9m). These results were after exiting over 60 sub-scale accounts in late 2020, as part of a refocusing on key accounts in scale markets.

 

Date of publication of interim results

The Board expects to publish interim results in mid September 2021 when it will provide a further update on current trading.

 

Stephen Moon, CEO of Science in Sport plc, said:

 

"The Group has regained its growth momentum after the unprecedented global disruption of the pandemic in 2020, returning to 20%+ growth rates. This very encouraging performance reflects the progress achieved in 2020 and the strength of our premium brands, and will help to drive strong underlying EBITDA growth.

 

"Growth is across all key markets, especially online, which is a key strategic area for us. Online sales increased by 44%, and now account for 54% of total sales, up from 46% a year ago, underpinned by our increased investment in online technology. Retail sales both in the UK and internationally moved past last year's comparatives and have further to go.

 

"Prospects for further progress in the second half look strong, and our long-term growth strategy remains unchanged."

 

Science in Sport plc

T: 020 7400 3700

Stephen Moon, CEO

James Simpson, CFO

Liberum (Nominated adviser and broker)

T: 020 3100 2000

Richard Lindley, James Greenwood, Will Hall

KTZ Communications

T: 020 3178 6378

Katie Tzouliadis, Dan Mahoney

 

About Science in Sport plc

www.sisplc.com

Headquartered in London, Science in Sport plc is a leading sports nutrition business that develops, manufactures and markets innovative nutrition products for professional athletes, sports and fitness enthusiasts and the active lifestyle community. The Company has two highly regarded brands, PhD Nutrition, a premium active-nutrition brand targeting the active lifestyle community, and SiS, a leading endurance nutrition brand among elite athletes and professional sports teams.

 

The two brands are sold internationally through the Company's phd.com and scienceinsport.com digital platforms, third-party online sites, including Amazon and Tmall, and an extensive retail distribution in the UK and internationally, including major supermarkets, high street chains and specialist sports retailers. This omnichannel footprint enables the Company to address the full breadth of the sports nutrition market, forecast to be £13 billion worldwide by 2023.

 

PhD is one of the UK's leading active nutrition brands with a reputation for high quality and product innovation. The brand has grown rapidly, based on its core protein powders, since its launch in 2005. The range now comprises powders, bars and supplements, including the high protein, low sugar range, PhD Smart. PhD brand ambassadors include leading fitness influencers Ross Edgley and Obi Vincent. The PhD brand is an official partner to the Tough Mudder Challenge and Race Series.

 

SiS, founded in 1992, has a core range comprising gels, powders and bars focused on energy, hydration and recovery. SiS is an official sports nutrition supplier to over 250 professional teams, organisations and national teams around the world, including INEOS Grenadiers Cycling Team. SiS supplies more than 150 professional football clubs in the UK, Europe and the USA and is Performance Research Partner to the English Football Association.

 

For further information, please visit phd.com and scienceinsport.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFIDDTIVLIL
Date   Source Headline
21st Mar 20187:00 amRNSOlympic Champion Adam Peaty Becomes SIS Ambassador
14th Feb 201810:49 amRNSHolding(s) in Company
9th Feb 20183:17 pmRNSHolding(s) in Company
9th Feb 20183:16 pmRNSHolding(s) in Company
8th Feb 20183:37 pmRNSHolding(s) in Company
18th Jan 20184:41 pmRNSIssue of Equity
18th Jan 20187:00 amRNSSiS becomes Official Partner of Manchester United
17th Jan 20183:44 pmRNSHolding(s) in Company
16th Jan 20187:00 amRNSPre-Close Trading Update
6th Dec 20174:47 pmRNSHolding(s) in Company
6th Dec 201710:29 amRNSHolding(s) in Company
6th Dec 201710:27 amRNSHolding(s) in Company
6th Dec 201710:20 amRNSHolding(s) in Company
5th Dec 20177:00 amRNSHolding(s) in Company
4th Dec 20171:22 pmRNSDirector/PDMR Shareholding
1st Dec 201712:44 pmRNSResults of General Meeting and Open Offer
14th Nov 20177:00 amRNSFirm Placing and Open Offer
27th Oct 20177:00 amRNSSiS announces partnership with Rock 'n' Roll
27th Oct 20177:00 amRNSSiS announces three-year deal with USA Triathlon
20th Sep 20179:06 amRNSHalf-year Report - Replacement
20th Sep 20177:00 amRNSHalf-year Report
12th Sep 20172:43 pmRNSHolding(s) in Company
11th Sep 20177:00 amRNSTHREE MORE YEARS FOR SiS AND TEAM SKY
4th Aug 20177:00 amRNSSIS to fuel leading British football clubs
3rd Aug 20177:00 amRNSNotice of Results
20th Jul 20177:00 amRNSHalf Year Trading Update
26th Jun 20174:30 pmEQSCavendish Asset Management: Paul Mumford named Small Cap Awards' Fund Manager of the Year
26th Jun 201712:29 pmRNSDirector/PDMR Shareholding
21st Jun 201712:44 pmRNSResult of AGM
20th Jun 20178:00 amRNSPDMR Dealing
15th Jun 20177:00 amRNSSIS to fuel British Triathlon
30th May 20177:00 amRNSSIS granted patent for novel WHEY20
19th May 20175:17 pmRNSPosting of Annual Report
18th May 20177:00 amRNSSIS to Fuel Cycling Australia To Tokyo 2020
12th May 20179:00 amRNSHolding(s) in Company
3rd May 20179:23 amRNSHolding(s) in Company
23rd Mar 20171:00 pmRNSPDMR Dealings and Issue of Equity
23rd Mar 20177:00 amRNSFinal Results
2nd Mar 20179:15 amRNSTotal Voting Rights
19th Jan 20178:44 amRNSHolding(s) in Company
17th Jan 20177:00 amRNSSIS Extends World Class Banned Substance Testing
10th Jan 20177:00 amRNSSIS To Fuel British Cycling To Tokyo 2020
9th Jan 20175:24 pmRNSIssue of Equity
5th Jan 20177:00 amRNSPre-Close Trading Update
29th Nov 20167:00 amRNSSiS receives award from Investors in People
17th Nov 20167:00 amRNSDirector/PDMR Shareholding
16th Nov 20167:00 amRNSDirector/PDMR Shareholding
27th Oct 20167:00 amRNSDirector/PDMR Shareholding
18th Oct 20167:00 amRNSAppointment of US Country Manager
26th Sep 20164:09 pmRNSNew Long Term Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.